A new article from ACP is designed to help primary care physicians address barriers in transgender medical care.
To address barriers in transgender medical care, the ACP published an article as part of a special series titled “In the Clinic” to help primary care physicians understand medical issues specific to transgender patients.
Studies estimate that 0.6% of U.S. adults, or 1.4 million persons, are transgender.
“Barriers to accessing appropriate and culturally competent care contribute to health disparities in transgender persons, such as increased rates of certain types of cancer, substance abuse, mental health conditions, infections, and chronic diseases.,” the authors Joshua D. Safer, MD, of Mount Sinai Health System and Icahn School of Medicine, and Vin Tangpricha, MD, PhD, of Emory University School of Medicine and the Atlanta VA Medical Center, wrote.
Two major guidelines are mentioned by the authors in the special series, published in the Annals of Internal Medicine: The World Professional Association for Transgender Health’s Standards of Care (SOC) for the Health of Transsexual, Transgender, and Gender Nonconforming People and the Endocrine Society’s Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.
Related: Studies Suggest ACA Helps with Healthcare Disparities
The authors advise clinicians to watch for signs and symptoms of depression, anxiety, and suicidality due to the higher rates of these conditions within the transgender population.
“The basic idea of this practical information is that a physician can make the diagnosis of gender dysphoria with adequate experience and training and initiate and monitor hormone therapy,” Tangpricha tells Managed Healthcare Executive.
“Treatment for people with gender dysphoria and gender non-conformity is medically necessary and should be covered under most medical benefits. Transgender and gender non-conforming people have effective medical and surgical options that shouldn't be denied because of differences in gender expression.”
There are four takeaways for healthcare executives, according to Tangpricha:
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with Ceci Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
The Departments of Health and Human Services (HHS), Labor, and the Treasury, released final rules on short-term, limited-duration insurance (STLDI) and independent, non-coordinated excepted benefits coverage, addressing issues related to the low-quality insurance, or "junk insurance" plans.
Read More
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and Ceci Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
March 28th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More
Muthiah “Muthu” Vaduganathan Discusses the Role of SGLT2 Inhibitors in Heart Failure Treatment
March 27th 2024Editors of Managed Healthcare Executive spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.
Read More